A Phase III, Double-masked, Multicenter, Randomized, Active Treatment-controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an As-needed Basis (PRN) in Patients With Sub-foveal Neovascular Age-related Macular Degeneration

Trial Profile

A Phase III, Double-masked, Multicenter, Randomized, Active Treatment-controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an As-needed Basis (PRN) in Patients With Sub-foveal Neovascular Age-related Macular Degeneration

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2016

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Choroidal neovascularisation; Wet age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Acronyms HARBOR
  • Sponsors Genentech
  • Most Recent Events

    • 15 Aug 2014 New trial record
    • 17 Jan 2013
    • 12 Nov 2010
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top